BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yeung C, Hilton J, Clemons M, Mazzarello S, Hutton B, Haggar F, Addison CL, Kuchuk I, Zhu X, Gelmon K, Arnaout A. Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review. Cancer Metastasis Rev 2016;35:427-37. [PMID: 27405651 DOI: 10.1007/s10555-016-9631-3] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 8.8] [Reference Citation Analysis]
Number Citing Articles
1 Pinto D, Schmitt F. Current applications of molecular testing on body cavity fluids. Diagn Cytopathol 2020;48:840-51. [PMID: 32227635 DOI: 10.1002/dc.24410] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
2 Lim E, Palmieri C, Tilley WD. Renewed interest in the progesterone receptor in breast cancer. Br J Cancer 2016;115:909-11. [PMID: 27657336 DOI: 10.1038/bjc.2016.303] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
3 Kalra J, Baker J, Song J, Kyle A, Minchinton A, Bally M. Inter-Metastatic Heterogeneity of Tumor Marker Expression and Microenvironment Architecture in a Preclinical Cancer Model. Int J Mol Sci 2021;22:6336. [PMID: 34199298 DOI: 10.3390/ijms22126336] [Reference Citation Analysis]
4 Zhou F, Zhou Y, Dong J, Tan W. Circulating endothelial cells and their subsets: novel biomarkers for cancer. Biomark Med 2017;11:665-76. [PMID: 28597689 DOI: 10.2217/bmm-2017-0143] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
5 Pizzuti L, Barba M, Mazzotta M, Krasniqi E, Maugeri-Saccà M, Gamucci T, Berardi R, Livi L, Ficorella C, Natoli C, Cortesi E, Generali D, La Verde N, Cassano A, Bria E, Moscetti L, Michelotti A, Adamo V, Zamagni C, Tonini G, Sergi D, Marinelli D, Paoletti G, Tomao S, Botticelli A, Marchetti P, Tinari N, Grassadonia A, Valerio MR, Mirabelli R, Fabbri MA, D'Ostilio N, Veltri E, Corsi D, Garrone O, Paris I, Sarobba G, Meattini I, Pistelli M, Giotta F, Lorusso V, Garufi C, Russo A, Cazzaniga M, Del Medico P, Roselli M, Vaccaro A, Perracchio L, di Benedetto A, Daralioti T, Sperduti I, De Maria R, Di Leo A, Sanguineti G, Ciliberto G, Vici P. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial. Sci Rep 2021;11:13770. [PMID: 34215766 DOI: 10.1038/s41598-021-92774-z] [Reference Citation Analysis]
6 Zhao L, Liu C, Xing Y, He J, O'Doherty J, Huang W, Zhao J. Development of a 99mTc-Labeled Single-Domain Antibody for SPECT/CT Assessment of HER2 Expression in Breast Cancer. Mol Pharm 2021;18:3616-22. [PMID: 34328338 DOI: 10.1021/acs.molpharmaceut.1c00569] [Reference Citation Analysis]
7 Yokota A, Hiramoto M, Hino H, Tokuhisa M, Miyazaki M, Kazama H, Takano N, Miyazawa K. Sequestosome 1 (p62) accumulation in breast cancer cells suppresses progesterone receptor expression via argonaute 2. Biochem Biophys Res Commun 2020;531:256-63. [PMID: 32800344 DOI: 10.1016/j.bbrc.2020.07.058] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Pérez-García J, Cortez P, Gion M, Cortés J. Can we cure oligometastatic disease? A practical point of view. Curr Opin Oncol 2020;32:568-74. [PMID: 32925203 DOI: 10.1097/CCO.0000000000000684] [Reference Citation Analysis]
9 Paquette M, Phoenix S, Lawson C, Guérin B, Lecomte R, Tai LH, Turcotte ÉE, Leyton JV. A preclinical PET dual-tracer imaging protocol for ER and HER2 phenotyping in breast cancer xenografts. EJNMMI Res 2020;10:69. [PMID: 32592121 DOI: 10.1186/s13550-020-00656-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Thulin A, Andersson C, Werner Rönnerman E, De Lara S, Chamalidou C, Schoenfeld A, Kovács A, Fagman H, Enlund F, Linderholm BK. Discordance of PIK3CA and TP53 mutations between breast cancer brain metastases and matched primary tumors. Sci Rep 2021;11:23548. [PMID: 34876602 DOI: 10.1038/s41598-021-02903-x] [Reference Citation Analysis]
11 Matsui A, Murata Y, Masuda N, Mori K, Takahashi M, Yamashiro K, Aogi K, Maeda S, Itou M, Ozaki S, Kuraoka K, Satou Y, Ichihara S, Tokunaga E, Taguchi K, Watanabe T, Suzuki H, Nagayama A, Nishimura R. Clinical significance of evaluating hormone receptor and HER2 protein using cell block against metastatic breast cancer: a multi-institutional study. Oncotarget 2019;10:5680-9. [PMID: 31620243 DOI: 10.18632/oncotarget.27163] [Reference Citation Analysis]
12 Yi ZB, Yu P, Zhang S, Wang WN, Han YQ, Ouyang QC, Yan M, Wang XJ, Hu XC, Jiang ZF, Huang T, Tong ZS, Wang SS, Yin YM, Li H, Yang RX, Yang HW, Teng YE, Sun T, Cai L, Li HY, Chen X, He JJ, Liu XL, Yang SE, Wang JY, Fan JH, Qiao YL, Xu BH. Profile and outcome of receptor conversion in breast cancer metastases: a nation-wide multicenter epidemiological study. Int J Cancer 2021;148:692-701. [PMID: 32700765 DOI: 10.1002/ijc.33227] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 Grüntkemeier L, Khurana A, Bischoff FZ, Hoffmann O, Kimmig R, Moore M, Cotter P, Kasimir-Bauer S. Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™-HER2-FISH workflow. Breast Cancer 2022. [PMID: 35025065 DOI: 10.1007/s12282-022-01330-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Jung J, Lee SH, Park M, Youn JH, Shin SH, Gwak HS, Yoo H. Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis. J Neurooncol 2018;137:295-302. [PMID: 29260362 DOI: 10.1007/s11060-017-2717-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
15 Bushnell GG, Wicha MS, Jeruss JS, Shea LD. Precision health for breast cancer metastasis: biomaterial scaffolds as an engineered metastatic niche to define, study, and monitor metastatic progression. Oncoscience 2019;6:380-2. [PMID: 31984215 DOI: 10.18632/oncoscience.493] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
16 Yang Z, Li N, Li X, Lei L, Wang X. The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients. Onco Targets Ther 2020;13:853-63. [PMID: 32099389 DOI: 10.2147/OTT.S231493] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
17 Ignatov T, Gorbunow F, Eggemann H, Ortmann O, Ignatov A. Loss of HER2 after HER2-targeted treatment. Breast Cancer Res Treat 2019;175:401-8. [DOI: 10.1007/s10549-019-05173-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
18 Tse T, Sehdev S, Seely J, Gravel DH, Clemons M, Cordeiro E, Arnaout A. Neoadjuvant Chemotherapy in Breast Cancer: Review of the Evidence and Conditions That Facilitated Its Use during the Global Pandemic. Curr Oncol 2021;28:1338-47. [PMID: 33805031 DOI: 10.3390/curroncol28020127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Zeng Y, Xu X, Wang S, Zhang Z, Liu Y, Han K, Cao B, Mao X. Ring finger protein 6 promotes breast cancer cell proliferation by stabilizing estrogen receptor alpha. Oncotarget 2017;8:20103-12. [PMID: 28223545 DOI: 10.18632/oncotarget.15384] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
20 Bannoura S, Nahouli H, Noubani A, Flaifel A, Khalifeh I. Characteristics of Breast Cancer Metastasizing to Bone in a Mediterranean Population. Cureus 2020;12:e11679. [PMID: 33391916 DOI: 10.7759/cureus.11679] [Reference Citation Analysis]
21 Bado I, Gugala Z, Fuqua SAW, Zhang XH. Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis. Oncogene. 2017;36:4527-4537. [PMID: 28368409 DOI: 10.1038/onc.2017.94] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
22 Peng L, Zhang Z, Zhao D, Zhao J, Mao F, Sun Q. Discordance of immunohistochemical markers between primary and recurrent or metastatic breast cancer: A retrospective analysis of 107 cases. Medicine (Baltimore) 2020;99:e20738. [PMID: 32569215 DOI: 10.1097/MD.0000000000020738] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Yu J, Li NL. Loss of human epidermal receptor-2 in human epidermal receptor-2+ breast cancer after neoadjuvant treatment: A case report. World J Clin Cases 2022; 10(17): 5923-5928 [DOI: 10.12998/wjcc.v10.i17.5923] [Reference Citation Analysis]
24 Bottoni G, Piccardo A, Fiz F, Siri G, Matteucci F, Rocca A, Nanni O, Monti M, Brain E, Alberini JL, Dib B, Sacchetti GM, Saggia C, Rossi V, Harbeck N, Wuerstlein R, Degenhardt T, DeCensi A, Rollandi GA, Gennari A. Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT. Eur J Radiol 2021;141:109821. [PMID: 34139575 DOI: 10.1016/j.ejrad.2021.109821] [Reference Citation Analysis]
25 Lindbo S, Garousi J, Mitran B, Vorobyeva A, Oroujeni M, Orlova A, Hober S, Tolmachev V. Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with 111In and 68Ga. Mol Pharm 2018;15:2674-83. [PMID: 29865791 DOI: 10.1021/acs.molpharmaceut.8b00204] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
26 McAnena PF, McGuire A, Ramli A, Curran C, Malone C, McLaughlin R, Barry K, Brown JAL, Kerin MJ. Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options. BMC Cancer 2018;18:203. [PMID: 29463223 DOI: 10.1186/s12885-018-4101-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
27 Davidson B. Molecular Cytology of Serous Effusions. In: Schmitt FC, editor. Molecular Applications in Cytology. Cham: Springer International Publishing; 2018. pp. 103-15. [DOI: 10.1007/978-3-319-74942-6_6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Tang M, Zeng X, Luo J, Quan FF, Chen CY, Li YK, Liu J, Zhang QF. Gene commander in the trash heap: Transcriptional regulation and ubiquitination modification mediated by RNF6 in carcinogenesis. Exp Cell Res 2021;401:112396. [PMID: 33485842 DOI: 10.1016/j.yexcr.2020.112396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Walter V, Fischer C, Deutsch TM, Ersing C, Nees J, Schütz F, Fremd C, Grischke EM, Sinn P, Brucker SY, Schneeweiss A, Hartkopf AD, Wallwiener M. Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer. Breast Cancer Res Treat 2020;183:137-44. [PMID: 32613540 DOI: 10.1007/s10549-020-05746-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
30 Fiz F, Bottoni G, Treglia G, Trimboli P, Piccardo A. Diagnostic and Prognostic Role of 18F-Fluoroestradiol PET in Metastatic Breast Cancer: The Second Youth of an Older Theranostic Concept. JCM 2022;11:3589. [DOI: 10.3390/jcm11133589] [Reference Citation Analysis]
31 Qazi MS, McGregor SM. Combined use of SOX10 and GATA3 in mammary carcinoma. Pathol Res Pract 2020;216:152801. [PMID: 31924335 DOI: 10.1016/j.prp.2019.152801] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
32 Schrijver WAME, Suijkerbuijk KPM, van Gils CH, van der Wall E, Moelans CB, van Diest PJ. Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis. J Natl Cancer Inst 2018;110:568-80. [PMID: 29315431 DOI: 10.1093/jnci/djx273] [Cited by in Crossref: 81] [Cited by in F6Publishing: 72] [Article Influence: 27.0] [Reference Citation Analysis]
33 Bièche I, Coussy F, El-Botty R, Vacher S, Château-Joubert S, Dahmani A, Montaudon E, Reyes C, Gentien D, Reyal F, Ricci F, Nicolas A, Marchio C, Vincent-Salomon A, Laé M, Marangoni E. HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast. J Hematol Oncol 2021;14:143. [PMID: 34496925 DOI: 10.1186/s13045-021-01158-3] [Reference Citation Analysis]
34 Vornicova O, Naroditsky I, Boyango I, Shachar SS, Mashiach T, Ilan N, Vlodavsky I, Bar-Sela G. Prognostic significance of heparanase expression in primary and metastatic breast carcinoma. Oncotarget. 2017;9:6238-6244. [PMID: 29464068 DOI: 10.18632/oncotarget.23560] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
35 Ronchi A, Pagliuca F, Zito Marino F, Accardo M, Cozzolino I, Franco R. Current and potential immunohistochemical biomarkers for prognosis and therapeutic stratification of breast carcinoma. Semin Cancer Biol 2021;72:114-22. [PMID: 32165319 DOI: 10.1016/j.semcancer.2020.03.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
36 Verschoor N, Deger T, Jager A, Sleijfer S, Wilting SM, Martens JW. Validity and utility of HER2/ERBB2 copy number variation assessed in liquid biopsies from breast cancer patients: a systematic review. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102384] [Reference Citation Analysis]
37 Siddiqui MT, Schmitt F, Churg A. Proceedings of the American Society of Cytopathology companion session at the 2019 United States and Canadian Academy of Pathology Annual meeting, part 2: effusion cytology with focus on theranostics and diagnosis of malignant mesothelioma. Journal of the American Society of Cytopathology 2019;8:352-61. [DOI: 10.1016/j.jasc.2019.07.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
38 Zhao J, Hu C, Wang C, Yu W, Guo Y, Shi M, Shui Y, Wei Q. Breast cancer primary tumor ER expression pattern predicts its expression concordance in matched synchronous lymph node metastases. BMC Cancer 2018;18:1290. [PMID: 30587150 DOI: 10.1186/s12885-018-5217-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Arici S, Hamdard J, Sakin A, Sengiz Erhan S, Atci MM, Cekin R, Saka B, Köse E, Saydam T, Geredeli C, Cihan S, Bilici A. The conversion of RAS status in metastatic colorectal cancer patients after first-line biological agent treatment. Colorectal Dis 2021;23:206-12. [PMID: 33002301 DOI: 10.1111/codi.15389] [Reference Citation Analysis]
40 Shien T, Tanaka T, Tanabe M, Okumura Y, Masuda N, Yoshida A, Arima N, Komoike Y, Tanaka S, Iwase T, Taguchi T, Nakatsukasa K, Inaji H, Ishitobi M; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Evaluation of ALDH1 expression in ipsilateral breast cancer recurrence. Oncol Lett 2017;13:1071-7. [PMID: 28454215 DOI: 10.3892/ol.2016.5538] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
41 Clinton LK, Plesec T, Goldblum JR, Hajifathalian K, Downs-kelly E, Patil DT. Specific Histopathologic Features Aid in Distinguishing Diffuse-type Gastric Adenocarcinoma From Metastatic Lobular Breast Carcinoma. American Journal of Surgical Pathology 2020;44:77-86. [DOI: 10.1097/pas.0000000000001341] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
42 Lu Y, Tong Y, Chen X, Shen K. Association of Biomarker Discrepancy and Treatment Decision, Disease Outcome in Recurrent/Metastatic Breast Cancer Patients. Front Oncol 2021;11:638619. [PMID: 34277399 DOI: 10.3389/fonc.2021.638619] [Reference Citation Analysis]
43 Luo X, Xie H, Yang Y, Zhang C, Zhang Y, Li Y, Yang Q, Wang D, Luo Y, Mai Z, Xie C, Yin S. Radiomic Signatures for Predicting Receptor Status in Breast Cancer Brain Metastases. Front Oncol 2022;12:878388. [PMID: 35734585 DOI: 10.3389/fonc.2022.878388] [Reference Citation Analysis]
44 Ramani VC, Lemaire CA, Triboulet M, Casey KM, Heirich K, Renier C, Vilches-Moure JG, Gupta R, Razmara AM, Zhang H, Sledge GW, Sollier E, Jeffrey SS. Investigating circulating tumor cells and distant metastases in patient-derived orthotopic xenograft models of triple-negative breast cancer. Breast Cancer Res 2019;21:98. [PMID: 31462307 DOI: 10.1186/s13058-019-1182-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
45 Lin Y, Wong SI, Wang Y, Lam C, Peng X. Periampullary Metastases from Breast Cancer: A Case Report and Literature Review. Case Rep Oncol Med 2019;2019:3479568. [PMID: 30729053 DOI: 10.1155/2019/3479568] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Bittner AK, Keup C, Hoffmann O, Hauch S, Kimmig R, Kasimir-Bauer S. Molecular characterization of circulating tumour cells identifies predictive markers for outcome in primary, triple-negative breast cancer patients. J Cell Mol Med 2020;24:8405-16. [PMID: 32558176 DOI: 10.1111/jcmm.15349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
47 Ercolani G. A Positive Conversion of Hormone Receptor Status Might Improve Survival after Liver Resection for Breast Metastases: Reply to Dr. Altundag. Dig Surg 2019;36:90. [PMID: 29597207 DOI: 10.1159/000488218] [Reference Citation Analysis]
48 Peng L, Zhang Z, Zhao D, Zhao J, Mao F, Sun Q. Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases. Pathol Oncol Res 2021;27:599894. [PMID: 34257555 DOI: 10.3389/pore.2021.599894] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Kannan A, Philley JV, Hertweck KL, Ndetan H, Singh KP, Sivakumar S, Wells RB, Vadlamudi RK, Dasgupta S. Cancer Testis Antigen Promotes Triple Negative Breast Cancer Metastasis and is Traceable in the Circulating Extracellular Vesicles. Sci Rep 2019;9:11632. [PMID: 31406142 DOI: 10.1038/s41598-019-48064-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]